Do DSM-5 substance use disorder criteria differ by user care settings? An item response theory analysis approach.

DSM-5 Differential item functioning Harm reduction setting Patient seeking treatment Substance use disorder

Journal

Addictive behaviors
ISSN: 1873-6327
Titre abrégé: Addict Behav
Pays: England
ID NLM: 7603486

Informations de publication

Date de publication:
05 2021
Historique:
received: 17 12 2019
revised: 07 11 2020
accepted: 20 12 2020
pubmed: 16 1 2021
medline: 15 5 2021
entrez: 15 1 2021
Statut: ppublish

Résumé

To examine differences in the psychometric characteristics of diagnostic criteria for Substance Use Disorders (SUD) between substance users in harm reduction settings (HR) and substance users seeking treatment (Tx). Differential Item and Test Functioning (DIF & DTF) analysis were performed to examine differences in the difficulty of endorsement and in discrimination of the 11 diagnostic criteria and to test if the criteria set as a whole (the "test") functioned differently by care settings (Tx vs. HR) for alcohol, cocaine, cannabis, opiates and tobacco. To test uniform and nonuniform DIF, multiple indicator multiple cause (MIMIC) structural equation models were used. Regardless of the substance, the DSM-5 criteria "craving", "large amount", "time spent", "tolerance" and "activities given up" had similar functioning by care settings. Little evidence for DIF was found for other criteria. The criteria set as a whole did not function differently by care settings for alcohol, cocaine and tobacco. At the same trait severity, compared to HR, the Tx subgroup had a greater number of endorsed criteria for cannabis and a smaller number of endorsed criteria for opioids. The unidimensionality of the 11 DSM-5 criteria and applicability of all criteria and diagnosis was confirmed in this large sample of problematic substance users. While the majority of the criteria related to loss of control of substance use, functioned well in both care settings, the criteria related to consequences of substance use had several differential functioning.

Identifiants

pubmed: 33450665
pii: S0306-4603(20)30926-6
doi: 10.1016/j.addbeh.2020.106797
pii:
doi:

Substances chimiques

Cocaine I5Y540LHVR

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106797

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA018652
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA025309
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

C Kervran (C)

University of Bordeaux, Addiction Team, Sleep Addiction and Neuropsychiatry Laboratory (SANPSY), Bordeaux, France; USR CNRS 3413, Bordeaux, France; Pôle Addictologie, CH Ch. Perrens and CHU de Bordeaux, Bordeaux, France.

D Shmulewitz (D)

New York State Psychiatric Institute, New York, NY, United States; Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States.

F Serre (F)

University of Bordeaux, Addiction Team, Sleep Addiction and Neuropsychiatry Laboratory (SANPSY), Bordeaux, France; USR CNRS 3413, Bordeaux, France; Pôle Addictologie, CH Ch. Perrens and CHU de Bordeaux, Bordeaux, France.

C Denis (C)

University of Bordeaux, Addiction Team, Sleep Addiction and Neuropsychiatry Laboratory (SANPSY), Bordeaux, France; USR CNRS 3413, Bordeaux, France; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

P Roux (P)

Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, Marseille, France.

M Jauffret-Roustide (M)

Cermes3, Inserm U988, CNRS UMR 8236, Université de Paris, EHESS, Paris, France; British Columbia Centre on Substance Use (BCCSU), Vancouver, Canada; Baldy Center for Law and Social Policy, Buffalo University of Social Sciences, Buffalo, NY, United States.

L Lalanne (L)

INSERM 1114, Department of Psychiatry and Addictology, University Hospital of Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.

D Hasin (D)

Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States.

M Auriacombe (M)

University of Bordeaux, Addiction Team, Sleep Addiction and Neuropsychiatry Laboratory (SANPSY), Bordeaux, France; USR CNRS 3413, Bordeaux, France; Pôle Addictologie, CH Ch. Perrens and CHU de Bordeaux, Bordeaux, France; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: marc.auriacombe@u-bordeaux.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH